copper chelate comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Identity and purity are established with a combination of chromatographic and spectroscopic techniques. Reversed-phase high-performance liquid chromatography separates the intact complex from peptide fragments and free copper, and the elution profile yields a purity estimate. Mass spectrometry gives the mass of the intact species and exposes degradation products. Ultraviolet-visible spectroscopy displays a broad absorption band in the visible region that is characteristic of the copper center. Nuclear magnetic resonance is less informative here, because the paramagnetic metal broadens signals and complicates spectral interpretation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Coordination compound rather than a simple salt |
| Peptide sequence | Glycyl-L-histidyl-L-lysine | Abbreviated GHK in most literature |
| Molecular formula | C14H22N6O4Cu | Reported for the 1:1 complex |
| Principal binding site | Histidine imidazole nitrogen | Backbone amides contribute additional coordination |
| Common synonym | Copper tripeptide-1 | Used in ingredient and product labelling |
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, frequently paired with mass spectrometry to confirm the molecular ion. Copper content is measured separately, typically by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy, because the chromatographic signal reports the peptide rather than the metal. Ultraviolet-visible spectroscopy provides a fast check on complex formation, since copper(II) peptide complexes absorb in the visible region. Elemental analysis and amino acid analysis are used less often but remain useful for reference standards. A gap between reported peptide purity and measured copper content is a recurring source of confusion.
Material described as GHK-Cu appears in several distinct markets, including cosmetic ingredients, laboratory reagents, and consumer products, and the quality expectations attached to each differ. A certificate of analysis generally reports peptide purity by chromatography, copper content, appearance, and residual solvents or counterions. Counterion identity matters, because the complex is usually supplied as an acetate or a similar salt, and the counterion contributes to the measured mass. Independent verification of sequence and metal stoichiometry is advisable when a material is used for quantitative work. Batch-to-batch variation is common and should be documented rather than assumed negligible.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
He called the bill "crony capitalism" and set several conditions for acceptance of the bill: "Companies must agree to issue warrants or equity stakes to the federal government; they must commit to not buying back their own stock, outsourcing American jobs overseas or repealing existing collective bargaining agreements; and they must remain neutral in any union organizing efforts". In April 2023, Sanders endorsed Biden in the 2024 United States presidential election, and after Biden withdrew from the race, Sanders endorsed Harris for president at the Democratic National Convention. Sanders attempted to appeal to pro-Palestinian critics of Harris by saying, "I promise you, after Kamala wins, we will together do everything that we can to change US policy toward Netanyahu", and emphasizing Donald Trump's policies on climate change, minimum wage, and tax cuts for the wealthy.
1. "Unichem, Optimus enter into strategic tie-up”. The Hindu Business Line.com. Published on 5 November 2018. 2. “Unichem to acquire 20% stake in Optimus group for Rs 120 cr”. Business-standard.com. Published on 5 November 2018. 3. “Unichem Labs gets USFDA nod for asthma drug”. Economictimes.com. Published on 4-July-2018. 4. “Unichem Labs' Ghaziabad unit gets EIR from USFDA” Thebusinessline.com. Published on 5 June 2018. 2018. 5. “Unichem Laboratories Gets ANDA Approval from U.S. FDA for Valsartan Tablets, USP.” Reuters.com. Published on 7 May 2018. 6. “How Torrent Pharma is integrating Unichem to boost its domestic business.” Business-standard.com. Published on 13 February 2018. 7. “Torrent Pharma completes acquisition of Unichem Laboratories Ltd.” Economictimes.com. Published on 14 December 2017. 8. “This conventional businessman is set for second innings”. Economictimes.indiatimes.com. Published on 4 November 2017. 9. “Unichem Labs gets EIR from USFDA for Goa facility” Economics times.com. Published on 30 June 2017. 10. "Unichem Lab appoints Mr. Bhagwat S. Dhingra as Chief Executive-Domestic Pharma". Moneycontrol.com. 13 August 2012. 11. "Contact Pharmaceutical Company India - Unichem Laboratories". Unichemlabs.com. Retrieved 3 October 2010. 12. "Interview of Dr P A Mody, CEO, Unichem Laboratories Ltd". Indiainfoline.com. Retrieved 3 October 2010. 13. "BSE Plus". Bseindia.com. Retrieved 3 October 2010. 14. "Pharmaceutical Business, Pharma Business Development - Unichem Laboratories". Unichemlabs.com. Retrieved 3 October 2010. 15.
=== Development and key milestones === Early discoveries in the 1990s included fullerene derivatives mimicking superoxide dismutase (SOD). The 2000s saw the term "nanozyme" formalized and applications expand, such as nanoceria preventing retinal degeneration and peroxidase-like activity in ferromagnetic nanoparticles for immunoassays. The 2010s brought numerous reviews and applications, including colorimetric assays, tumor visualization, and anti-biofouling. Key books and reviews emerged, summarizing progress. In the 2020s, nanozymes advanced in therapeutic applications, such as single-atom nanozymes for sepsis and tumor therapy. Strategies like data-informed discovery and machine learning aided discovery, and applications in treating conditions like Parkinson's disease, inflammatory bowel disease, stroke and traumatic brain injury were reported. Nanozymes were recognized as one of IUPAC's Top Ten Emerging Technologies in Chemistry in 2022. Nanozyme is among the Top 10 Emerging Technologies of 2025 Summer Davos. A monograph entitled nanozymes was published in Chinese (《纳米酶》). Nanozyme-enhanced implants were developed.
Sources: en.wikipedia.org
These channels are shut when the membrane potential is near the (negative) resting potential of the cell, but they rapidly begin to open if the membrane potential increases to a precisely defined threshold voltage, "depolarising" the membrane. When the channels open, they allow an inward flow of sodium ions, which makes the interior of the cell more positive, which further raises the (negative) membrane potential. This then causes more channels to open, producing a greater electric current across the cell membrane and so on. The process proceeds explosively until all of the available ion channels are open, resulting in a large upswing in the membrane potential. The rapid influx of sodium ions causes the polarity of (i.e. the direction of the electric field across) the plasma membrane to reverse, and the ion channels then rapidly inactivate. As the sodium channels close, sodium ions can no longer enter the neuron, and they are then actively transported back out of the plasma membrane. Potassium channels are then activated, and there is an outward current of potassium ions, returning the electrochemical gradient to the resting state. Because few ions need to pass through to change the potential, the concentrations of ions on either side remain relatively unchanged during this process. After an action potential has occurred, there is a transient negative shift, called the afterhyperpolarization. In animal cells, there are two primary types of action potentials. One type is generated by voltage-gated sodium channels, the other by voltage-gated calcium channels.
In homolytic cleavage, or homolysis, the two electrons in a cleaved covalent bond are divided equally between the products. This process is also known as homolytic fission or radical fission. The bond-dissociation energy of a bond is the amount of energy required to cleave the bond homolytically. This enthalpy change is one measure of bond strength. The triplet excitation energy of a sigma bond is the energy required for homolytic dissociation, but the actual excitation energy may be higher than the bond-dissociation energy due to the repulsion between electrons in the triplet state.
== 2023 UFC Honors awards == Starting in 2019, the UFC created year-end awards with "UFC Honors President's Choice Awards" for categories "Performance of the Year" and "Fight of the Year" being chosen by UFC CEO Dana White. The other "UFC Honors Fan Choice Awards" are for categories "Knockout of the Year", "Submission of the Year", "Event of the Year", "Comeback of the Year" and, from 2020, "Debut of the Year" in which fans are able to vote for the winner on social media. Winners receive a trophy commemorating their achievement along with a set of tires from sponsor Toyo Tires.
=== Digestion and ageing === Digestion, or precipitate ageing, happens when a freshly formed precipitate is left, usually at a higher temperature, in the solution from which it precipitates. It results in purer and larger recrystallized particles. The physico-chemical process underlying digestion is called Ostwald ripening.
Sources: en.wikipedia.org
GHK denotes the unbound chain of three amino acids. GHK-Cu describes the form in which a copper(II) ion is held by that chain. The two are not interchangeable in solution, since charge, molecular weight, and reactivity differ.
The chain occurs in human plasma, saliva, and urine. Measured amounts are reported to fall with age. Copper binding by the sequence is treated as part of normal metal handling in tissue.
The bound copper(II) centre contributes to redox behaviour and to stability under physiological conditions. Free copper ions can participate in reactions that generate reactive species, while chelated metal is generally more controlled. The chain may also serve as a carrier for copper in experimental systems.
Lyophilized material is normally held at about minus twenty degrees Celsius in a sealed, desiccated vial. Dissolved samples are less durable and are prepared fresh. Repeated freeze-thaw cycles are avoided.